Kiraly P, Groznik AL, Valentinčič NV, Mekjavić PJ, Urbančič M, Ocvirk J, Mesti T. Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report. World J Clin Cases 2022; 10(19): 6536-6542 [PMID: 35979276 DOI: 10.12998/wjcc.v10.i19.6536]
Corresponding Author of This Article
Tanja Mesti, PhD, Assistant Professor, Department of Medical Oncology, Institute of Oncology Ljubljana, Zaloška 2, Ljubljana 1000, Slovenia. tmesti@onko-i.si
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 6, 2022; 10(19): 6536-6542 Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6536
Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report
Peter Kiraly, Alenka Lavrič Groznik, Nataša Vidovič Valentinčič, Polona Jaki Mekjavić, Mojca Urbančič, Janja Ocvirk, Tanja Mesti
Peter Kiraly, Alenka Lavrič Groznik, Nataša Vidovič Valentinčič, Polona Jaki Mekjavić, Mojca Urbančič, Eye Hospital, University Medical Centre Ljubljana, Grablovičeva 46, SI-1000 Ljubljana, Slovenia
Peter Kiraly, Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, OX3 9DU, Oxford, United Kingdom
Janja Ocvirk, Tanja Mesti, Department of Medical Oncology, Institute of Oncology Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana 1000, Slovenia
Author contributions: Kiraly P was the patient’s ophthalmologist, collected the patient’s clinical data, reviewed the literature, designed the report, and wrote the paper; Groznik AL, Valentinčič NV, Mekjavić PJ, and Urbančič M were the patient’s ophthalmologists and contributed to manuscript drafting; Mesti T and Ocvirk J were the patient’s oncologists and contributed to manuscript drafting, writing, and editing.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tanja Mesti, PhD, Assistant Professor, Department of Medical Oncology, Institute of Oncology Ljubljana, Zaloška 2, Ljubljana 1000, Slovenia. tmesti@onko-i.si
Received: September 13, 2021 Peer-review started: September 13, 2021 First decision: January 10, 2022 Revised: November 12, 2021 Accepted: May 8, 2022 Article in press: May 8, 2022 Published online: July 6, 2022 Processing time: 283 Days and 19.4 Hours
Core Tip
Core Tip: The effectiveness of B-Raf proto-oncogene serine/threonine kinase (BRAF)/mitogen-activated protein kinase (MEK) inhibitor therapy in terms of prolonging survival has revolutionized the treatment of metastatic melanoma and other cancers. Consequently, widespread use in several metastatic cancers could be anticipated in the future. Therefore, all possible adverse effects should be described. We report a case of very rare and severe bilateral panuveitis with transient visual loss associated with treatment of metastatic malignant melanoma. The purpose of our case report is to raise awareness of possible severe bilateral panuveitis associated with immune checkpoint inhibitor therapy and to show that ocular symptoms subside with BRAF/MEK inhibitor discontinuation and/or systemic corticosteroids. Further studies should establish guidelines for panuveitis management and evaluate the importance of ophthalmological examination for asymptomatic patients.
